The what, why and how of bayesian clinical trials monitoring

Laurence S. Freedman; David J. Spiegelhalter; Mahesh K.B. Parmar

doi:10.1002/sim.4780131312

The what, why and how of bayesian clinical trials monitoring

Laurence S. Freedman
, David J. Spiegelhalter
, Mahesh K.B. Parmar

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5‐Fluorouracil for colorectal cancer.

Original language	English
Pages (from-to)	1371-1383
Number of pages	13
Journal	Statistics in Medicine
Volume	13
Issue number	13-14
DOIs	https://doi.org/10.1002/sim.4780131312
State	Published - 15 Jul 1994
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/sim.4780131312

Cite this

@article{01b5c617fb9f4c4b974c56ca082d3de5,

title = "The what, why and how of bayesian clinical trials monitoring",

abstract = "We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5‐Fluorouracil for colorectal cancer.",

author = "Freedman, \{Laurence S.\} and Spiegelhalter, \{David J.\} and Parmar, \{Mahesh K.B.\}",

year = "1994",

month = jul,

day = "15",

doi = "10.1002/sim.4780131312",

language = "אנגלית",

volume = "13",

pages = "1371--1383",

journal = "Statistics in Medicine",

issn = "0277-6715",

publisher = "John Wiley and Sons Ltd",

number = "13-14",

}

TY - JOUR

T1 - The what, why and how of bayesian clinical trials monitoring

AU - Freedman, Laurence S.

AU - Spiegelhalter, David J.

AU - Parmar, Mahesh K.B.

PY - 1994/7/15

Y1 - 1994/7/15

N2 - We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5‐Fluorouracil for colorectal cancer.

AB - We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5‐Fluorouracil for colorectal cancer.

UR - https://www.scopus.com/pages/publications/0028146249

U2 - 10.1002/sim.4780131312

DO - 10.1002/sim.4780131312

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 7973217

AN - SCOPUS:0028146249

SN - 0277-6715

VL - 13

SP - 1371

EP - 1383

JO - Statistics in Medicine

JF - Statistics in Medicine

IS - 13-14

ER -

The what, why and how of bayesian clinical trials monitoring

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this